127 related articles for article (PubMed ID: 33674959)
1. CT imaging findings of lenvatinib-induced enteritis.
Kurokawa R; Hagiwara A; Tanishima T; Inui S; Kurokawa M; Nakaya M; Gonoi W; Amemiya S; Nakai Y; Fujita N; Ota Y; Baba A; Abe O
Abdom Radiol (NY); 2021 Jul; 46(7):3066-3074. PubMed ID: 33674959
[TBL] [Abstract][Full Text] [Related]
2. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
3. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas.
Uchida-Kobayashi S; Kageyama K; Yamamoto A; Ikenaga H; Yoshida K; Kotani K; Kimura K; Odagiri N; Hagihara A; Fujii H; Enomoto M; Tamori A; Kubo S; Miki Y; Kawada N
Oncology; 2021; 99(3):186-191. PubMed ID: 33032274
[TBL] [Abstract][Full Text] [Related]
6. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
7. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.
Hata K; Suetsugu K; Egashira N; Makihara Y; Itoh S; Yoshizumi T; Tanaka M; Kohjima M; Watanabe H; Masuda S; Ieiri I
Cancer Chemother Pharmacol; 2020 Dec; 86(6):803-813. PubMed ID: 33095285
[TBL] [Abstract][Full Text] [Related]
8. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
Cabanillas ME; Takahashi S
Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
[TBL] [Abstract][Full Text] [Related]
9. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.
Koizumi Y; Hirooka M; Hiraoka A; Ochi H; Tanaka T; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Miyake T; Matsuura B; Michitaka K; Joko K; Abe M; Hiasa Y
Endocr J; 2019 Sep; 66(9):787-792. PubMed ID: 31142692
[TBL] [Abstract][Full Text] [Related]
11. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
Yamashige D; Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Kajiwara A; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Oncology; 2021; 99(3):169-176. PubMed ID: 33207358
[TBL] [Abstract][Full Text] [Related]
12. Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.
Miyajima S; Tsuji K; Kito Y; Yoshida N; Matsunaga K; Tsuji S; Katayanagi K; Yonezawa M; Kubo A; Ushijima K; Minato H; Doyama H
Clin J Gastroenterol; 2021 Feb; 14(1):187-192. PubMed ID: 33025343
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.
Obi S; Sato T; Sato S; Kanda M; Tokudome Y; Kojima Y; Suzuki Y; Hosoda K; Kawai T; Kondo Y; Isomura Y; Ohyama H; Nakagomi K; Ashizawa H; Miura Y; Amano H; Mochizuki H; Omata M
Hepatol Int; 2019 Mar; 13(2):199-204. PubMed ID: 30671808
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma.
Masaki C; Sugino K; Saito N; Saito Y; Tanaka T; Ogimi Y; Maeda T; Osaku T; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
Endocr J; 2017 Aug; 64(8):819-826. PubMed ID: 28659544
[TBL] [Abstract][Full Text] [Related]
15. Minimal impact of lenvatinib (Lenvima®) on muscle mass in advanced hepatocellular carcinoma and implications for treatment duration. Two cases from the REFLECT study.
Rinninella E; Cintoni M; Raoul P; Mele MC; De Gaetano AM; Marini MG; Mora V; Gasbarrini A
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):10132-10138. PubMed ID: 31799685
[TBL] [Abstract][Full Text] [Related]
16. Incidence and computed tomography findings of lenvatinib-induced pancreatobiliary inflammation: A single-center, retrospective study.
Kurokawa R; Inui S; Tanishima T; Nakaya M; Kurokawa M; Ishida M; Gonoi W; Amemiya S; Nakai Y; Ishigaki K; Tateishi R; Koike K; Abe O
Medicine (Baltimore); 2021 Sep; 100(35):e27182. PubMed ID: 34477177
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem.
Nervo A; Ragni A; Gallo M; Ferraris A; Fonio P; Piovesan A; Arvat E
Thyroid; 2020 Feb; 30(2):229-236. PubMed ID: 31854230
[No Abstract] [Full Text] [Related]
18. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
Haddad RI; Schlumberger M; Wirth LJ; Sherman EJ; Shah MH; Robinson B; Dutcus CE; Teng A; Gianoukakis AG; Sherman SI
Endocrine; 2017 Apr; 56(1):121-128. PubMed ID: 28155175
[TBL] [Abstract][Full Text] [Related]
19. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.
Tamai T; Hayato S; Hojo S; Suzuki T; Okusaka T; Ikeda K; Kumada H
J Clin Pharmacol; 2017 Sep; 57(9):1138-1147. PubMed ID: 28561918
[TBL] [Abstract][Full Text] [Related]
20. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
